Compare Valero Energy Corporation (VLO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Valero Energy Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Valero Energy Corporation trades at $434.88 (market cap $127.78B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Valero Energy Corporation is far larger — about 12.6× State Street SPDR S&P Biotech ETF's market cap, and Valero Energy Corporation pays a 1.08% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Valero Energy Corporation for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VLO | XBI | |
|---|---|---|
Market Cap | $127.78B | $10.11B |
Volume | 2,570,225 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $443.80 | $169.55 |
52-Week Low | $156.39 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $131.26B | — |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Valero Energy (VLO) trades at $433.75, up 2.28% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest overbought conditions. Fundamentally, VLO has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. The company maintains a solid balance sheet with a debt-to-asset ratio of 18.31% as of 2024.
VLO's outlook is supported by robust refining margins and a favorable analyst consensus, with 54% buy ratings and a $408.10 price target. Key risks include potential diesel export bans and volatile energy markets. Investors should weigh strong cash flow projections against cyclical industry headwinds for balanced exposure.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
